PT-141 (Bremelanotide): From Research Peptide to Approved Medicine
PT-141 is a melanocortin-receptor research peptide that completed Phase-3 trials and reached FDA approval as bremelanotide in 2019. The melanocortin system, and the pipeline arc it illustrates.
PT-141 (bremelanotide) is notable for a reason most research peptides are not: it completed Phase-3 trials and reached regulatory approval. This article explains the melanocortin system it targets and how PT-141 progressed.
The melanocortin system
PT-141 is a cyclic heptapeptide that activates the melanocortin receptors MC3R and MC4R. Unlike compounds that act on the vascular system, PT-141 works centrally through the melanocortin pathway - a different mechanism entirely.
From melanotan-II to bremelanotide
PT-141 is a derivative of the earlier research peptide melanotan-II. They are related but distinct, with different receptor profiles. PT-141 progressed through clinical development and, in 2019, was approved by the FDA as bremelanotide (trade name Vyleesi) for a specific indication.
A worked example of the peptide pipeline
PT-141 is a useful case study because it shows the full arc a research peptide can travel: from an early experimental compound, through structured Phase-3 trials, to an approved, regulated medicine. It is the kind of trajectory that underlines why peptide science is a serious pharmaceutical discipline.
Quality and verification
Caesar Biomedical PT-141 ships as a research compound with per-lot HPLC and mass-spec verification, independently confirmed in Dubai or the UK.
Explore the compound
PT-141
Bremelanotide · melanocortin-receptor research peptide
Frequently asked questions
- Is PT-141 the same as melanotan-II?
- They are related - PT-141 (bremelanotide) is a derivative of melanotan-II - but they are distinct compounds with different receptor profiles. The exact compound is stated on the Certificate of Analysis.
- PT-141 is FDA-approved - does that mean I can use it?
- The approved drug bremelanotide (Vyleesi) is a regulated prescription medicine. The research compound sold here is for laboratory research use only and is not a substitute for a prescribed medicine.
For laboratory research use only. This article references published preclinical and clinical literature and is not medical advice, a therapeutic claim, or a recommendation for human use.